Pelthos Therapeutics Inc. PTHS 深 沪
等待开盘 08-27 09:30:00 美东时间
26.78
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 26.78
- 总市值 1.03亿
- 52周最高 37.50
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 18.19
- 委 比 0.00%
- 总股本 382.85万
- 历史最高 60.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 4.50
- 每 手 1
- 风险率 3.59%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pelthos Therapeutics Earnings Call Highlights Strong Momentum
Pelthos Therapeutics Inc. (($PTHS)) has held its Q2 earnings call. Read on for ...
08-23 08:23
Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026
Pelthos Therapeutics Inc. will report its second quarter 2026 financial results on Thursday, August 13, 2026, followed by a conference call at 8:30 a.m. ET. Participants can join via phone using the toll-free number 1-877-451-6152 (US) or 1-201-389-0879 (international), using Conf.ID 13761132, or via the provided CallMe link. A webcast option is also available. Pelthos is a biopharmaceutical company focused on developing therapeutic products for ...
08-03 12:00
Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders
Pelthos Therapeutics Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on September 29, 2026, at 9:00 a.m. Eastern Time. Stockholders of record as of August 4, 2026, are entitled to vote. The meeting date differs by more than 30 days from the 2025 meeting, requiring stockholder proposals under Rule 14a-8 to be submitted by August 3, 2026. Pelthos, a commercial-stage biopharmaceutical company, focuses on developing trea...
07-24 21:00
Pelthos Therapeutics Joins The Russell 3000E Growth Benchmark, Russell Microcap And Russell Microcap Growth Benchmark Indexes
Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, ("Pelthos"), today announced that the company was added as a member of the Russell 3000E™ Growth Benchmark, Russell Microcap®, and Russell Microcap...
07-01 04:17
Pelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark Indexes
Pelthos Therapeutics Inc. was added to the Russell 3000E™ Growth Benchmark, Russell Microcap®, and Russell Microcap® Growth Benchmark Indexes effective June 29, 2026. The reconstitution captures the 4,000 largest U.S. stocks by market capitalization and occurs semi-annually. CEO Scott Plesha stated the inclusion reflects Pelthos' progress since becoming public and will enhance visibility in the investment community. Russell indexes, managed by FT...
06-30 20:15
Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
Pelthos Therapeutics Inc. announced that CEO Scott Plesha will present at the Jefferies Global Healthcare Conference on June 4, 2026, in New York. The presentation will take place at 11:05 am ET, and Scott will also participate in one-on-one investor meetings. Investors interested in scheduling meetings should contact their Jefferies representative. Pelthos is a biopharmaceutical company focused on commercializing innovative therapies for unmet p...
05-28 21:00
美股大行评级 | 应用材料获17家大行集体上调目标价；Bitdeer 、Forgent 、嘉信理财、Viking等获多家大行上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从11美元升至12美元；Ladenburg Thalmann：维持Usio"买入"评级，目标价从5.75美元升至6.25美元
05-18 11:48
Oppenheimer Maintains Outperform on Pelthos Therapeutics, Raises Price Target to $66
Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and raises the price target from $62 to $66.
05-15 21:26
Pelthos Therapeutics Q1 2026 Earnings Call Transcript
Pelthos Therapeutics (AMEX:PTHS) reported first-quarter financial results on Th...
05-14 22:06
Earnings Scheduled For May 14, 2026
Companies Reporting Before The Bell • Urban One (NASDAQ:UONEK) is expected to r...
05-14 19:11
